Throughout this series, we have discussed that for eligible patients, the current standard of care is to take patients for autologous stem cell transplant as consolidation for their multiple myeloma. In this reboot episode, we sit down with two incredible hematologists who specialize in transplant to discuss the real-life decision-making that goes into evaluating each patient. We are so excited to welcome two special guests this week, Dr. Shonali Midha and Dr. Amar Kelkar, joining us from the Dana-Farber Cancer Institute in Boston!

Content:

- What goes into determining if a patient is transplant eligible?

- What counseling is provided to patients?

- Approach to melphalan dosing

- How does apheresis work?

- What agents are used to help mobilize stem cells?

- How many stem cells do we need to collect?

- Does how much therapy one has received affect their collection?

- Is there still a role for transplant in today's world?

- Is there a role for an "MRD-adapted" approach to treatment?

- Is there a role for a second transplant in patients who have relapsed?

- Is there a role for allogeneic stem cell transplants in myeloma?

A huge THANK YOU to our guests, Dr. Shonali Midha and Dr. Amar Kelkar, both of the Dana-Farber Cancer Institute!

** Want to review the show notes for this episode and others? Check out our website.

Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!

Twitter: @TheFellowOnCall

Instagram: @TheFellowOnCall

Listen in on: Apple Podcast, Spotify, and Youtube

Episode 148: Myeloma Series, Pt. 8- Transplant in Multiple Myeloma (2026)

The Fellow on Call: The Heme/Onc Podcast